$ACLX News
Last published 6mo ago
- 6mo agoACLXGILDGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celBusiness WireGilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115
- 8mo agoONCYLLYGILDACLX+1Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 BillionPR Newswirehe global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035, as immunotherapy...
- 8mo agoACLXGETYIBRXKBLBBiotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media MegamergerGlobeNewswireDENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and
- 8mo agoACLXGILDGilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-celBusiness Wire– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with
- 8mo agoACLXGILDGilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celBusiness Wire– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with
- 9mo agoACLXArcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain BinderBusiness Wire-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- -- No tonic signaling or off-target
- 9mo agoACLXArcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem MeetingsBusiness Wire-- The D-Domain binder has a fast off-rate and contributes to anito-cel's differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use ahead of bispecific antibodies in 4L+ RRMM is
- 11mo agoACLXArcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple MyelomaBusiness Wire-- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%,
- 11mo agoACLXArcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and ExpositionBusiness WireSaturday, December 6, 2025 at 8:00 p.m. ET Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
- 1y agoACLXArcellx Provides Third Quarter 2025 Financial ResultsBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial
- 1y agoACLXArcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and ExpositionBusiness Wire-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome,
- 1y agoACLXArcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoACLXArcellx to Participate at the 2025 Morgan Stanley Global Healthcare ConferenceBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
- 1y agoACLXArcellx Provides Second Quarter 2025 Financial Results and Business HighlightsBusiness Wire-- Presented preliminary data from a May 1, 2025 data cutoff date for all 117 patients with a median follow-up of 12.6 months in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM -- -- 97% ORR,
- 1y agoONCYAKYAQTRXTCRX+1New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer BiotechsPR NewswireEquity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...
- 1y agoACLXArcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025Business WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming
- 1y agoACLXArcellx Provides First Quarter 2025 Financial Results and Business HighlightsBusiness Wire-- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise
- 1y agoACLXArcellx Appoints Andrew Galligan and Kristin Myers to Its Board of DirectorsBusiness Wire-- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy
- 1y agoACLXArcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness MonthGlobeNewswireNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ:ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark,
- 1y agoACLXArcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business HighlightsBusiness Wire-- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which demonstrated 97% ORR and 62% CR/sCR at a median follow-up of
- 1y agoACLXArcellx to Participate at the TD Cowen 45th Annual Health Care ConferenceBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
- 1y agoACLXArcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and ExpositionBusiness Wire-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months -- -- No delayed neurotoxicities have been
- 2y agoACLXArcellx Provides Third Quarter 2024 Financial Results and Business HighlightsBusiness Wire-- Recently released ASH abstracts for the company's Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety
- 2y agoACLXArcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 StudyBusiness Wire-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients enrolled in the
- 2y agoACLXArcellx Provides Second Quarter 2024 Financial Results and Business UpdatesBusiness Wire-- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment -- -- Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting -- -- The global Phase 3 trial, iMMagine-3, has been
- 2y agoACLXGILDArcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be
- 2y agoACLXGILDKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be
- 2y agoACLXArcellx Provides First Quarter 2024 Financial ResultsBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business
- 2y agoACLXArcellx to Participate in Two Upcoming Investor ConferencesBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
- 2y agoACLXArcellx to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
- 2y agoACLXArcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceBusiness WireArcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
- 2y agoACLXArcellx to Participate at the TD Cowen 44th Annual Health Care ConferencePR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 2y agoACLXArcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business HighlightsPR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 2y agoACLXArcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASHPR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 2y agoACLXGILDKite and Arcellx Announce Expansion in Strategic PartnershipBusiness Wire-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive
- 2y agoACLXGILDARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIPPR NewswireArcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced that the companies have expanded their existing...
- 2y agoACLXArcellx Provides Third Quarter 2023 Financial Results and Business HighlightsPR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 3y agoACLXArcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and ExpositionPR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 3y agoACLXArcellx to Participate in Two Upcoming Investor ConferencesPR NewswireArcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
- 3y agoACLXArcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial ResultsPR Newswire-- Company expects to present preliminary data from iMMagine-1 study in 2H'24 -- REDWOOD CITY, Calif., Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy
- 3y agoACLXArcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical ProgramPR Newswire-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology
- 3y agoACLXArcellx Provides First Quarter Financial ResultsPR NewswireREDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
- 3y agoACLXArcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual ConferencePR NewswireREDWOOD CITY, Calif., April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
- 3y agoACLXArcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business HighlightsPR Newswire-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion
- 3y agoACLXArcellx to Participate at the H.C. Wainwright Cell Therapy Virtual ConferencePR NewswireREDWOOD CITY, Calif., Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
- 3y agoACLXArcellx to Participate in Upcoming Investor ConferencesPR NewswireREDWOOD CITY, Calif., Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
- 3y agoACLXGILDKite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness WireKite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize Arcellx's lead
- 3y agoACLXArcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline ProgressPR Newswire-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12
- 3y agoACLXGILDKite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness Wire-- Collaboration Leverages Expertise Across Both Companies, Including Kite's Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc.
- 3y agoACLXGILDArcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple MyelomaPR Newswire-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity